bIf you’re looking for easy ways to generate consistent income in Canada and haven’t tried yet, you could be missing out on one of the simplest and most reliable strategies for building wealth. By focusing on stocks that pay , you can set up a steady income stream to cover expenses, reinvest for growth, or save for future goals. What’s great is that the Canadian stock market is filled with top-tier dividend stocks, making it easy to enjoy a stress-free monthly paycheck. In this article, I’ll highlight two strong Canadian stocks that could help you earn the easiest monthly paycheck for years to secure financial peace of mind. Exchange Income stock Based on its long-term fundamentals, ( ) is one of Canada’s top monthly dividend-paying stocks, making it a great choice for investors seeking stable income. This Winnipeg-based diversified company mainly focuses on aviation services and manufacturing sectors. In aviation, it operates regional airlines and provides related services, especially in remote and underserved areas. On the manufacturing side, it produces specialized equipment like precision metal products and communication systems. After surging by 25.5% year to date, EIF stock currently trades at $56.62 per share with a of $2.7 billion. While the company distributes its dividends every month, it offers a 4.7% annualized dividend yield at the current market price. In the third quarter, Exchange Income delivered record revenue of $709.9 million with growth across its Aerospace & Aviation and Manufacturing segments. Its aviation operations thrived, benefiting from new medevac contracts and increased demand for its aircraft leasing services, while the Manufacturing segment saw an uptick in orders as economic uncertainty began to ease. Moreover, the company expects its strategic acquisitions, such as Spartan Mat, to expand its footprint in niche markets, boosting long-term growth potential. With a free cash flow payout ratio of just 60% for the trailing twelve months and a 4.7% dividend yield, Exchange Income stock looks really attractive for income-focused investors. Mullen Group stock Another great Canadian stock to consider for monthly dividend income is ( ). This Okotoks-based logistics and transportation company’s main focus is tracking, warehousing, and oilfield services. It currently has a market cap of $1.3 billion as its stock trades at $15.37 per share with nearly 10% year-to-date gains. At this market price, MTL stock offers an attractive 5.4% annualized dividend yield. Mullen has consistently proven its ability to adapt and thrive, even in a challenging economic environment. In the quarter ended in September 2024, the company posted record revenue of $532 million, not only showing 5.6% year-over-year growth but also exceeding Bay Street’s expectations. This strong top-line growth was mainly supported by strategic acquisitions and robust performance in its Logistics & Warehousing business segment, which grew by an impressive 23.2% from a year ago to $168.9 million. Despite softness in freight demand and competitive pricing pressures in other areas, the company’s efficient cost management and diversified business model led to a 7.6% surge in its quarterly operating income before depreciation and amortization. Overall, Mullen’s continued focus on acquiring high-value businesses and debt optimization brightens its long-term growth outlook, making it a reliable monthly dividend stock to own for the long term.
Real Madrid's big stars turned on the style to revive the Spanish giant's faltering Champions League title defense on Tuesday. Galacticos Kylian Mbappe, Vinicius Junior and Jude Bellingham all scored in a thrilling 3-2 win at Italian league leader Atalanta. But Madrid still had to ride its luck as Mateo Retegui fired over from in front of goal in stoppage time when handed a golden chance to level the game. It was only Madrid's third win in the competition's revamped league phase and leaves the 15-time champion in the unseeded playoff positions in 18th place. Mbappe was substituted off before halftime with an apparent physical issue. Six-time champion Liverpool leads the way after maintaining its perfect record in Europe this season with a 1-0 win against Girona. Like Madrid, Paris Saint-Germain also picked up a much-needed win, beating Salzburg 3-0 to sit in the last playoff spot in 24th place. Bayer Leverkusen is second after a 1-0 win over Inter Milan, while Aston Villa beat Leipzig 3-2 and is third. Brest is one of this season's surprise packages on its Champions League debut and is fifth after beating PSV Eindhoven 1-0. Salah's landmark Mohamed Salah’s 50th Champions League goal maintained Liverpool’s perfect record in the competition this season. The Egypt forward struck a 63rd minute penalty to seal the win in Spain that kept Liverpool atop the 36-team league. But even after a sixth straight win for the Merseyside club, head coach Arne Slot was critical of his players in a game that saw goalkeeper Alisson pull off several saves to keep Girona out. “If you ask me about all the six games, I’m really pleased with all the results, I am really pleased with the five (other) games with the way we played. I’m far from pleased about the performance tonight,” he said. Salah’s goal was his 16th in 22 appearances overall this season. Girona was 30th with just one win from six games. “I almost feel sorry for them because they deserved so much more in this Champions League campaign than the three points they have until now. But we have an incredible goalkeeper,” Slot said. Even after Slot’s criticism, Liverpool continued its outstanding start to the campaign, which also led it the top of the Premier League. Former Manchester United midfielder Donny van de Beek handed Salah the chance to fire the visitors ahead with a clumsy tackle from behind on Luis Diaz in the box. Salah stepped up to convert the penalty and Girona goalkeeper Paulo Gazzaniga went the wrong way. Liverpool’s two remaining games are against Lille at home and PSV Eindhoven away in January. U.S. international Christian Pulisic is the only player to have scored against Liverpool in this season’s Champions League in a 3-1 loss for Milan in September. Bayern rout Bayern Munich routed Shakhtar Donetsk 5-1 to move into the automatic qualifying positions for the round of 16. Michael Olise scored twice as Bayern came back from going 1-0 down inside five minutes to a goal from Brazilian winger Kevin. Sporting Lisbon couldn’t build on taking a third-minute lead at Club Brugge — losing 2-1 in Belgium. Dinamo Zagreb drew 0-0 with Celtic and both teams remain in the playoff positions. ___ James Robson is at https://twitter.com/jamesalanrobson ___ AP soccer: https://apnews.com/hub/soccer James Robson, The Associated PressParis Saint-Germain have work to do if they are to qualify for the last 16 of the Champions League after a 1-0 defeat at Bayern Munich. ( More Football News ) Kim Min-jae's first-half header proved decisive at Allianz Arena on Tuesday, with Ousmane Dembele's red card after the break making the task even tougher for PSG. Having won just once in the competition so far – back in their opening game against Girona – Luis Enrique's team were second-best for much of the contest. BY Stats Perform Bayern dominated the first half, with Kingsley Coman particularly dangerous, and the Bundesliga leaders got the goal their performance merited when Kim headed home from a corner in the 38th minute, with PSG's stand-in goalkeeper Matvey Safonov in no man's land. Dembele, who had seen a decent attempt saved by Manuel Neuer in the first half, received his marching orders for a lunge on his France team-mate Coman just before the hour, with the referee deeming it worthy of a second booking. It marked the first time Dembele has been sent off since 2019, when he saw red for Barcelona in a LaLiga clash with Sevilla. Safonov made amends for his earlier mistake by tipping a Jamal Musiala shot onto the post but despite applying some late pressure, PSG could not prevent Bayern from claiming a seventh consecutive victory and seventh straight clean sheet in all competitions. While Vincent Kompany's team are up to 11th in the standings, PSG are in 26th on just four points from their five matches, two places outside of the play-off spots with three games remaining. 33 – FC Bayern Munich are unbeaten in each of their last 33 home games in the UEFA Champions League group stage respectively league phase (W31 D2), the joint-longest such run in the competition's history, level with FC Barcelona between 2009 and 2020. Fortress. pic.twitter.com/2tNxidpNL1 Data Debrief: Kim off the mark for buoyant Bayern Kim scored his first goal in the Champions League, in what was his 23rd appearance in the competition. The scoreline ultimately flattered PSG, who finished with 0.88 expected goals (xG), while Bayern created 2.21 xG. Bayern are now unbeaten in each of their last 33 home games in the Champions League group stage (W31 D2), the joint-longest such run in the competition's history, level with Barcelona between November 2009 and November 2020. They have gone on a run of seven wins without conceding for the first time since September 2011, too. This is the eighth time in the Champions League that Bayern have defeated PSG, with only Real Madrid (11 vs Bayern) and Bayern themselves (10 vs Barcelona) winning more games against a single opponent in the competition's history.
All Black Ops 6 weapons buffed with less recoil, reduced sway, and increased headshot damageNEW YORK , Dec. 12, 2024 /PRNewswire/ -- Report with market evolution powered by AI - The global biologics contract development and manufacturing organization (CDMO) market size is estimated to grow by USD 10.63 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 10.46% during the forecast period. Availability of cost-efficient resources in emerging markets is driving market growth, with a trend towards advent of big data. However, capacity utilization and constraints poses a challenge. Key market players include 3P BIOPHARMACEUTICALS S.L.U, AbbVie Inc., AGC Biologics, Binex Co. Ltd., Boehringer Ingelheim International GmbH, Bora Pharmaceuticals Co. Ltd, Catalent Inc., Evonik Industries AG, FUJIFILM Corp., Grifols SA, J RETTENMAIER and SOHNE GmbH and Co KG, JSR Corp., Kemwell Biopharma Pvt. Ltd., Lonza Group Ltd., Novartis AG, Rentschler Biopharma SE, Samsung Electronics Co. Ltd., Shenzhen Hepalink Pharmaceutical Co. Ltd., Toyobo Co. Ltd., and WuXi Biologics Cayman Inc.. AI-Powered Market Evolution Insights. Our comprehensive market report ready with the latest trends, growth opportunities, and strategic analysis- View Free Sample Report PDF Key Market Trends Fueling Growth The Biologics Contract Development and Manufacturing Organization (CDMO) market is experiencing significant growth, particularly in the areas of small molecules and large molecules, including biologics, biosimilars, cancer therapies, monoclonal antibodies, and vaccines. This trend is driven by the increasing demand for specialized expertise and advanced technology in the production of complex biological medicinal products. Niche CDMOs and biopharmaceutical CDMOs are leading the way in the production of biologics, such as recombinant proteins and monoclonal antibodies, using cutting-edge technology like advanced manufacturing technologies, single-use/disposable bioreactors, and automation. The focus on infectious diseases, chronic diseases, and novel therapies, such as immunotherapy, is also driving growth in the market. The disease landscape is constantly evolving, with an increasing focus on evidence-based practice and the development of treatments for conditions like diabetes, geriatric population, and metabolic illnesses. Supply chain management, quality testing, and third-party logistic providers are essential components of the CDMO market, ensuring the production of high-quality biological medications and vaccinations. The use of advanced technology, such as software development and process engineering, is crucial for the production of complex biological molecules, including nucleic acids, cell receptors, and post-translational changes. Pharma clients require CDMOs to provide clinical services, from fermentation and tissue processing to cell bank creation and cell line engineering. The production of biological medications and vaccinations requires a deep understanding of biology, as well as expertise in areas like myelosuppression, cardiotoxicity, renal insufficiency, and neurotoxicity. The CDMO market is expected to continue growing, with a focus on the production of small-molecule drugs, biopharmaceuticals, and biological medications, as well as the development of novel therapies for diseases like allergies, gene therapy, and metabolic syndrome. The use of advanced technology, specialized expertise, and niche CDMOs will be key to meeting the demands of the market and delivering high-quality products to patients. The pharmaceutical industry's technological advancements extend beyond drug research and development to data analytics. This tool is increasingly utilized for clinical data synthesis, expediting the drug development process. Big data is a popular strategy in healthcare, including pharmaceuticals, for informed research and development decisions. Data analytics effectively identifies potential new drug candidates, creates simulation models to assess drug efficacy, pinpoints patient populations through various sources, and monitors potential side effects for early avoidance. Biologics Contract Development and Manufacturing Organizations (CDMOs) leverage these analytics to streamline their services, ensuring efficient and effective drug development. Insights on how AI is driving innovation, efficiency, and market growth- Request Sample! Market Challenges The Biologics Contract Development and Manufacturing Organization (CDMO) market is experiencing significant growth due to the increasing demand for biologics, biosimilars, and novel therapies in various disease areas. However, this market faces challenges in producing both small molecules and large molecules, including biologics, monoclonal antibodies, and vaccines. The supply chain for these complex products requires advanced technology, specialized expertise, and collaboration with third-party logistic providers. Biologics CDMOs focus on biological medicinal products, such as recombinant proteins, monoclonal antibodies, and vaccines. They face challenges in producing these products using fermentation, microbial fermentation, and advanced manufacturing technologies, such as single-use/disposable bioreactors. Niche CDMOs specialize in areas like cancer therapies, infectious diseases, and rare diseases, requiring evidence-based practice and cutting-edge technology. The disease landscape includes chronic infectious diseases, ageing, and multisystem functional decline, affecting geriatric populations. These conditions require careful consideration of myelosuppression, cardiotoxicity, renal insufficiency, neurotoxicity, polypharmacy, and mental state. Biopharmaceutical CDMOs must ensure quality testing, automation, software development, process engineering, and biology expertise to meet the needs of pharma clients. The Biologics segment includes monoclonal antibodies, immunotherapy, and gene therapy, requiring tissue processing, cell bank creation, and cell line engineering. Novel therapies, such as nucleic acids, cell receptors, and metabolic illnesses, add complexity to the production process. The challenges of producing these biological molecules and managing their supply chain necessitate collaboration between CDMOs, pharma clients, and other stakeholders. The biologics Contract Development and Manufacturing Organization (CDMO) market is currently challenged by capacity utilization issues. Capacity utilization refers to the ratio of actual production to the potential production when a company's capacity is fully utilized. This measure plays a significant role in manufacturing various therapeutics, particularly biological drugs, due to the intricate production process. Approximately 35% of CDMOs encounter minor capacity utilization constraints during manufacturing, while 20% experience moderate to major constraints. These manufacturing constraints hinder CDMOs from reaching their full production potential, leading to delays in the release of numerous therapeutics. Insights into how AI is reshaping industries and driving growth- Download a Sample Report Segment Overview This biologics contract development and manufacturing organization (cdmo) market report extensively covers market segmentation by 1.1 Mammalian 1.2 Microbial 2.1 Biologics 2.2 Biosimilars 3.1 North America 3.2 Europe 3.3 Asia 3.4 Rest of World (ROW) 1.1 Mammalian- The mammalian segment holds a significant share in the global biologics Contract Development and Manufacturing Organization (CDMO) market due to the increasing use of mammalian cells in producing therapeutic proteins for various diseases. Mammalian cells, derived from mammalian tissue, are primarily used for growing animal cells in vitro, and there are four main types: fibroblasts, epithelial cells, lymphocytes, and macrophages. Lymphocytes are found in the blood, while the others are found in tissue. Mammalian cell culture is widely used for producing human proteins with high therapeutic potential, such as tissue plasminogen activators, clotting factors, and erythropoietin, which cannot be produced using bacteria or yeasts. Recombinant proteins from mammalian cells are used in therapeutics for conditions like diabetes and cancer. Additionally, mammalian cell culture technology is utilized for bulk vaccine production, contributing to market growth. For instance, Catalent Inc. Signed an agreement in June 2020 to develop a COVID-19 vaccine using its GPEx cell line development technology. Catalent offers comprehensive services, including mammalian cell line development, process development, process validation, formulation development, and drug substance manufacturing, from preclinical to commercial stages. These factors are expected to drive the growth of the mammalian segment in the global biologics CDMO market. Download complimentary Sample Report to gain insights into AI's impact on market dynamics, emerging trends, and future opportunities- including forecast (2024-2028) and historic data (2018 - 2022) Research Analysis The Biologics Contract Development and Manufacturing Organization (CDMO) market caters to the production of Biological Medicinal Products, including large molecules such as monoclonal antibodies, biosimilars, cancer therapies, and small molecules. These CDMOs play a crucial role in supplying the pharma industry with high-quality products, serving clients in various therapeutic areas like chronic infectious diseases and diabetes. Advanced manufacturing technologies, like single-use/disposable bioreactors, automation, and software development, are transforming the industry. Smaller, niche BioCDMOs also thrive, offering specialized services in areas like tissue processing and clinical services. The focus on quality testing ensures the production of safe and effective biological medicines, meeting regulatory requirements. Biopharmaceutical companies benefit from the expertise and capabilities of these CDMOs, streamlining their supply chain and accelerating time-to-market for new treatments. Market Research Overview The Biologics Contract Development and Manufacturing Organization (CDMO) market encompasses the production of biologics, including small molecules, large molecules, biosimilars, monoclonal antibodies, cancer therapies, and various specialized therapies such as vaccines, recombinant proteins, and novel therapies. This market caters to the supply chain needs of pharmaceutical clients, focusing on quality testing, third-party logistic providers, and advanced technology. Biologics CDMOs offer specialized expertise in areas like fermentation, microbial fermentation, and advanced manufacturing technologies, including single-use/disposable bioreactors. The market landscape includes a range of niche and biopharmaceutical CDMOs, serving various disease areas like infectious diseases, chronic diseases, and cancer. Cutting-edge technology and evidence-based practice are integral to the biologics CDMO sector, which includes the production of biological medicinal products, small-molecule drugs, and biopharmaceuticals. The biology of cells, tissue processing, cell bank creation, cell line engineering, and post-translational changes are crucial aspects of biologics production. The geriatric population, with ageing and multisystem functional decline, presents unique challenges, including myelosuppression, cardiotoxicity, renal insufficiency, neurotoxicity, polypharmacy, and mental state. Biologics CDMOs address these challenges through automation, software development, process engineering, and biology expertise. The biologics CDMO sector also covers the production of vaccinations, somatic cells, tissues, and various biological molecules, including nucleic acids, cell receptors, and metabolic illnesses like diabetes. Allergy treatments, gene therapy, and therapies for various diseases like cancer, infectious diseases, and metabolic syndrome are also part of the biologics CDMO market. Table of Contents: 1 Executive Summary 2 Market Landscape 3 Market Sizing 4 Historic Market Size 5 Five Forces Analysis 6 Market Segmentation Type Mammalian Microbial Product Type Biologics Biosimilars Geography North America Europe Asia Rest Of World (ROW) 7 Customer Landscape 8 Geographic Landscape 9 Drivers, Challenges, and Trends 10 Company Landscape 11 Company Analysis 12 Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: www.technavio.com/ SOURCE Technavio
Marvell Introduces 1.6 Tbps LPO Chipset to Enable Optical Short-reach, Scale-up Compute Fabric InterconnectsQU, edX launch first Arabic entrepreneurship certificate program
Adare Manor in Co Limerick is among the 'Best Hotels and Resorts in the World,' earning itself a spot on Condé Nast Traveler's Gold List 2025 , which was published on Wednesday, December 11. The award-winning Adare Manor is the only Irish inclusion on the prestigious list. The hotels and resorts featured on Condé Nast Traveler's Gold List 2025 are highlighted not only for their "beauty, comfort, or impeccable service," but also for the "deeply emotional relationships" that the publication's editors have developed with them. Adare Manor is among the hotels and resorts that Condé Nast Traveler editors "recommend to our friends, that we tell stories about later." Adare Manor, Co Limerick. (Ireland's Content Pool) Sign up to IrishCentral's newsletter to stay up-to-date with everything Irish! Here's what Condé Nast said about Adare Manor in its Gold List 2025: "Few country escapes can beat this 19th-century neo-Gothic castle in Ireland’s County Limerick. "First built for the Second Earl of Dunraven on an 842-acre estate, it features stained-glass windows, gold-leaf ceilings, and towering fireplaces, all restored to their original glory. "The signature suite’s classic-contemporary bedroom and bathroom overlook the boundless sprawl of gardens and the Ryder Cup golf course. "Guests can lord it in horse-and-buggy rides, go on clay-shooting and archery sessions, take padel tennis classes, eat Michelin-star suppers at the Oak Room, and afterward descend to the Tack Room cellar-lounge to sample its rare Irish whiskey collection. "Rural breaks have never felt so ennobling. From $640." Adare Manor, Co Limerick. (Ireland's Content Pool) "A golden year for Adare Manor," the Irish hotel said in a social media blast, adding that it is "honoured" to be included in Condé Nast Traveler Gold List 2025. "This recognition reflects the passion of our team and the unforgettable experiences we create for our guests. Here’s to continuing a gold standard of hospitality," the Irish hotel said. A post shared by Adare Manor (@theadaremanor) This is the second major nod Adare Manor has received from Condé Nast Traveler this year. In October, it was named the best resort in Europe as part of Condé Nast Traveler’s Readers’ Choice Awards 2024. This was the third year in a row Adare Manor claimed the title. Adare Manor, Co Limerick. (Ireland's Content Pool) While Adare Manor came out on top, six other Irish resorts were named among the top 25 best resorts in Europe: Ashford Castle in Co Mayo, Trump International Golf Links and Hotel Doonbeg in Co Clare, Sheen Falls Lodge in Co Kerry, Dromoland Castle Hotel & Country Estate in Co Clare, The Europe in Co Kerry, and The Dunloe in Co Kerry. Meanwhile, Co Clare was named one of the Best Places to Go in Europe for 2025 by Condé Nast Traveler.
'September 5' is gripping, tense, and hauntingRescata tu AFORE, specialists in recovering retirement savings for foreign workers 11-26-2024 11:16 PM CET | Business, Economy, Finances, Banking & Insurance Press release from: Getnews / PR Agency: Notorial Image: https://www.getnews.info/wp-content/uploads/2024/11/1732637593.jpeg Recovering retirement savings from Mexico's AFORE system can be a complex process for foreign workers. Many face challenges navigating the legal and administrative hurdles required to access these funds. Rescata tu AFORE [ https://rescatatuafore.com/ ] specializes in the recovery of retirement savings for foreign workers [ https://rescatatuafore.com/como-lo-hacemos/ ], offering tailored solutions designed to streamline the process and ensure clients receive their funds efficiently. This focus has established the company as a trusted partner for expatriates seeking financial clarity. Tailored solutions for recovering retirement savings AFORE accounts are private retirement savings funds managed by Mexican institutions, designed to hold contributions made by workers affiliated with IMSS or ISSSTE. For foreign workers, retrieving these savings after leaving the country can be particularly challenging due to regulatory complexities. Rescata tu AFORE addresses these obstacles by providing personalized services that guide clients through every step of the recovery process. The company's experienced team of economists and legal experts ensures that each case is handled with the utmost professionalism. Their deep understanding of Mexican regulations and international client needs allows them to deliver solutions that are both effective and transparent. Rescata tu AFORE's approach focuses on minimizing delays, avoiding unnecessary complications, and ensuring clients reclaim the funds they are entitled to. A commitment to supporting foreign workers Rescata tu AFORE not only facilitates the recovery of retirement savings but also raises awareness among foreign workers about their right to access these funds. Many expatriates are unaware of the existence of their AFORE accounts or the possibility of retrieving their contributions. By providing clear communication and expert guidance, the company bridges this knowledge gap, empowering workers to take control of their finances. The recovery of retirement savings for foreign workers represents a crucial service for those who have contributed to Mexico's social security system. Rescata tu AFORE continues to stand out for its commitment to efficiency and client satisfaction, ensuring that expatriates can access their savings with confidence and ease. Through their dedication to transparency and personalized service, the company has become a reliable partner for those seeking financial resolution. Media Contact Company Name: Joan Sans Contact Person: Press Office Email: Send Email [ http://www.universalpressrelease.com/?pr=rescata-tu-afore-specialists-in-recovering-retirement-savings-for-foreign-workers ] Country: United States Website: https://rescatatuafore.com/ This release was published on openPR.
Trudeau directs key adviser to deliver renewed national security strategy
All-star Vancouver Canucks goalie Thatcher Demko will make his first start of the season Tuesday. Head coach Rick Tocchet confirmed after morning skate that Demko will be in net when the Canucks host the St. Louis Blues. The 28-year-old netminder from San Diego, Calif., last played on April 24 when the Canucks bested the Nashville Predators in Game 1 of a first-round playoff series. He suffered an injury to the popliteus muscle in his knee during the game and has been working his way back ever since. A number of factors led to Demko starting Tuesday, Tocchet said. “You want him to feel comfortable. You want to, obviously, communicate with him,” he said. “(Kevin Lankinen) was playing well, too. So there wasn’t a pressing issue to get him in. But we want to get him in. We’re excited. Obviously he’s a huge part of our team.” Demko had a 35-14-2 record with a .918 save percentage, a 2.45 goals-against average and five shutouts in regular-season play last year and played in the all-star game for the second time in his career. The veteran goalie is managing his personal expectations as he returns to game action, however. “I think it’d be foolish to say that I’m going to come back and be perfectly sharp and feel like I have my ‘A’ game in game one. Obviously, that takes a little bit of time,” Demko told reporters last week. “Just seeing game reps and things is kind of a last step of fully doing rehab. So I’m not really putting an expectation on that. “Obviously, the way Lanks has played kind of takes a little bit of pressure off of myself to come in and not feel like I have to save the world.” Demko returned to Vancouver’s lineup last week, backing up Lankinen for games against the Columbus Blue Jackets and Tampa Bay Lightning. The Canucks signed Lankinen to a US$875,000 deal during training camp and the Finnish goaltender has split the crease with Arturs Silovs this season, backstopping Vancouver to a 14-8-4 record. Lankinen has been “unbelievable” this season, Demko said. “It’s been really fun to get to know him and be able to watch him play,” he said. “It’s a challenging position he was put in, coming into a new team and being able to manage the workload that he’s been given.” Demko’s return to the crease should act as motivation for the Canucks’ skaters as the team takes on the Blues, Tocchet said. “I think, when you look at the way Demmer has worked hard to get back, a lot of lonely times by himself, it should give guys juice that you want to play well in front of him,” the coach said. You’d be crazy not to. “Maybe there’s extra shot blocking, situations to get the puck in deep when we’re tired to give him a break, things like that. I think we need to do that tonight for him.”Rayonier Declares Special Dividend of $1.80 Per Share Payable 25% in Cash and 75% in Common SharesNone
Brazilian President Luiz Inacio Lula da Silva was in “stable” condition after emergency surgery yesterday for an intracranial haemorrhage and should leave the hospital next week, his doctors said. Lula, 79, was transported overnight to Brazil’s top medical facility, Hospital Sirio-Libanes in Sao Paulo, after experiencing headaches that medics found were related to a fall he suffered in October. The leader of South America’s largest country regained consciousness following the two-hour operation and was eating and talking, the doctors told a news conference. Vice-President Geraldo Alckmin had taken over Lula’s workload in the meantime. “After successful surgery, the anguish of last night has changed to calm and the certainty that, with the dedication of the medical team and faith and the people’s love, he will soon return to work,” Lula’s wife, First Lady Rosangela Janja da Silva, said on Instagram. The bleeding was linked to a fall Lula suffered on October 19, the hospital said. Lula had hit his head after falling in a bathroom at the presidential residence in the capital Brasilia and received several stitches. After experiencing a headache on Monday, a medical examination with an MRI scan in Brasilia found the intracranial haemorrhage. Lula was swiftly transported to Hospital Sirio-Libanes, where surgeons performed a trepanation — drilling into the skull to relieve pressure. “The bleeding was between the brain and the dura mater membrane,” a thick protective layer under the skull, and was located on the left side, above the frontal lobe and the parietal lobe, said Marcos Stavale, a doctor on the medical team. Through surgery, “the brain was decompressed and neurological functions were preserved,” he said. “He didn’t have brain damage” from the emergency, added another doctor, Roberto Kalil. Back in October, Lula cancelled a planned trip to Russia for a Brics summit following his fall, instead joining the meeting online. He also skipped a UN COP29 climate summit in Baku, the capital of Azerbaijan. Lula at the time described his accident as “serious” during a telephone call with an official from his Workers’ Party that was shared on social media. Since then, the Brazilian leader has maintained a busy schedule, including last month hosting the G20 summit in Rio de Janeiro and Chinese President Xi Jinping in Brasilia, and last week attending a summit of the Mercosur bloc in Uruguay. Lula has frequently talked about his good health and has said he wants to “live to 120.” The Brazilian leader has faced other health issues in the past. But just as in politics, the hyperactive leftist — who is half-way through his third term — has bounced back from every misfortune. In 1964, when he was a metalworker in a car parts factory, Lula lost the little finger on his left hand in a workplace accident. Lula, who was 19 at the time, said that a press broke and, when he tried to fix it, his finger was crushed. He went on to become a trade union leader before entering politics. Lula was forced to cancel a trip to the World Economic Forum in Davos in January 2010 after being admitted to hospital with alarmingly high blood pressure. He was 64 years old at the time and nearing the end of his second term. Doctors said he was suffering from stress and fatigue after a bout of flu. He was discharged from hospital after a few hours and subsequently quit smoking after fifty years. After leaving power in 2011, at 66, he was diagnosed with laryngeal cancer and underwent chemotherapy and radiotherapy. Doctors announced he had made a full recovery the following year, although his once-booming voice was left with a hoarseness that became a trademark on his campaign trail return. During the 2022 presidential race, which marked his stunning return to power after a year and a half behind bars on corruption charges, some of his opponents questioned his health because of his weak voice. Three weeks after his re-election, he underwent surgery to remove a lesion from his vocal cords. In September 2023, he received a hip replacement to relieve pain that had been bothering him for over a year. Lula suffers from osteoarthritis, or wear and tear on the cartilage that protects joints. The image-conscious president has since published videos of himself doing exercises in the presidential residence. He has not said whether he will run again in 2026 elections, telling CNN last month that “I’m going to think about 2026 in 2026.” “It’s not the youth that’s going to solve the world governance problems. What’s going to solve the world governance problem is the competence of the ruler, the mindset of the ruler, the health of those,” Lula said. “I will be willing to run again. But I hope it won’t be necessary. And I hope that we’ll have other candidates and so that we can have great political renovation in the country and in the world,” he added. Related Story Senegalese president arrives in Doha World leaders pledge to work with Trump after election triumph
When the NCAA's playing rules oversight committee this past spring approved the use of coach-to-player helmet communications in games for the 2024 season, Kolpacki, Michigan State's head football equipment manager, knew the Spartans' QBs and linebackers were going to have a problem. "There had to be some sort of solution," he said. As it turns out, there was. And it was right across the street. Kolpacki reached out to Tamara Reid Bush, a mechanical engineering professor who not only heads the school's Biomechanical Design Research Laboratory but also is a football season ticket-holder. Kolpacki "showed me some photos and said that other teams had just put duct tape inside the (earhole), and he asked me, 'Do you think we can do anything better than duct tape,?" Bush said. "And I said, 'Oh, absolutely.'" Bush and Rylie DuBois, a sophomore biosystems engineering major and undergraduate research assistant at the lab, set out to produce earhole inserts made from polylactic acid, a bio-based plastic, using a 3D printer. Part of the challenge was accounting for the earhole sizes and shapes that vary depending on helmet style. Once the season got underway with a Friday night home game against Florida Atlantic on Aug. 30, the helmets of starting quarterback Aidan Chiles and linebacker Jordan Turner were outfitted with the inserts, which helped mitigate crowd noise. DuBois attended the game, sitting in the student section. "I felt such a strong sense of accomplishment and pride," DuBois said. "And I told all my friends around me about how I designed what they were wearing on the field." All told, Bush and DuBois have produced around 180 sets of the inserts, a number that grew in part due to the variety of helmet designs and colors that are available to be worn by Spartan players any given Saturday. Plus, the engineering folks have been fine-tuning their design throughout the season. Dozens of Bowl Subdivision programs are doing something similar. In many cases, they're getting 3D-printed earhole covers from XO Armor Technologies, which provides on-site, on-demand 3D printing of athletic wearables. The Auburn, Alabama-based company has donated its version of the earhole covers to the equipment managers of programs ranging from Georgia and Clemson to Boise State and Arizona State in the hope the schools would consider doing business with XO Armor in the future, said Jeff Klosterman, vice president of business development. XO Armor first was approached by the Houston Texans at the end of last season about creating something to assist quarterback C.J. Stroud in better hearing play calls delivered to his helmet during road games. XO Armor worked on a solution and had completed one when it received another inquiry: Ohio State, which had heard Michigan State was moving forward with helmet inserts, wondered if XO Armor had anything in the works. "We kind of just did this as a one-off favor to the Texans and honestly didn't forecast it becoming our viral moment in college football," Klosterman said. "We've now got about 60 teams across college football and the NFL wearing our sound-deadening earhole covers every weekend." The rules state that only one player for each team is permitted to be in communication with coaches while on the field. For the Spartans, it's typically Chiles on offense and Turner on defense. Turner prefers to have an insert in both earholes, but Chiles has asked that the insert be used in only one on his helmet. Chiles "likes to be able to feel like he has some sort of outward exposure," Kolpacki said. Exposure is something the sophomore signal-caller from Long Beach, California, had in away games against Michigan and Oregon this season. Michigan Stadium welcomed 110,000-plus fans for the Oct. 26 matchup between the in-state rivals. And while just under 60,000 packed Autzen Stadium in Eugene, Oregon, for the Ducks' 31-10 win over Michigan State three weeks earlier, it was plenty loud. "The Big Ten has some pretty impressive venues," Kolpacki said. "It can be just deafening," he said. "That's what those fans are there for is to create havoc and make it difficult for coaches to get a play call off." Something that is a bit easier to handle thanks to Bush and her team. She called the inserts a "win-win-win" for everyone. "It's exciting for me to work with athletics and the football team," she said. "I think it's really exciting for our students as well to take what they've learned and develop and design something and see it being used and executed."Brazil police accuse Bolsonaro and ex-ministers of 2022 coup plotMarvell Announces Breakthrough Custom HBM Compute Architecture to Optimize Cloud AI Accelerators